Key result
Apolipoprotein B in atrial fibrillation often acts as a marker of competing systemic illness and atherosclerotic burden rather than a direct trigger of the arrhythmia.
Answers are grounded in this paper and cite their sources.
In patients with atrial fibrillation, low apolipoprotein B may be a marker of systemic illness rather than a protective factor, while high apolipoprotein B should prompt intensified atherosclerotic risk management.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Maj et al. (2026) conducted a letter in Atrial fibrillation. Apolipoprotein B in atrial fibrillation often acts as a marker of competing systemic illness and atherosclerotic burden rather than a direct trigger of the arrhythmia.
Synapse has enriched 10 related papers. Consider them for comparative context: